文献速递胸部肿瘤放疗放疗物理与技术

大运动幅度胸部肿瘤临床3D/4D累积质子剂量评估方法

Clinical 3D/4D cumulative proton dose assessment methods for thoracic tumours with large motion.
PubMed 文献 · Radiother Oncol · 2023-02-22

本研究对20例靶区运动幅度>10 mm的胸部肿瘤患者采用五次分层重扫描调强质子治疗(IMPT),比较4D临床前评估方法(4DREM)与临床3D/4D剂量重建累积方法(3DREM、4DREAL)在治疗疗程中的计划稳健性。结果显示所有患者靶区覆盖充分,4DREAL靶区覆盖最高(99.8±0.6%,p<0.001),3DREM与4DREM间无差异;解剖变化、摆位和射程误差对靶区覆盖的影响比运动更严重。

要点

  • 靶区运动11-17 mm的胸部肿瘤自由呼吸IMPT,各累积方法均显示靶区覆盖充分。
  • 4DREAL靶区覆盖最高(99.8±0.6%,p<0.001),3DREM与4DREM间无差异。
  • 解剖变化、摆位和射程误差对靶区覆盖的影响比运动更严重。

核心结论

  • 靶区运动幅度达17 mm的胸部肿瘤在自由呼吸下采用IMPT可得到充分治疗,任意累积方法均适用。
  • 在这些接受分次质子放疗的患者中,解剖变化、摆位和射程误差对靶区覆盖的影响比运动更严重。

研究设计与样本

  • 20例靶区运动>10 mm的患者接受五次分层重扫描IMPT,在平均计划4DCT上生成3D稳健优化计划。
  • 利用多次4DCT,通过3DREM(基于平均4DCT)、4DREM(含治疗实施时间结构和4DCT相位)及4DREAL(基于分次信息)按周和按治疗疗程评估计划稳健性。

主要发现

  • 所有患者基线靶区运动范围为11-17 mm。
  • 离线自适应疗程剂量评估显示所有患者靶区剂量覆盖充分。
  • 接受95%处方剂量的靶区体积在各方法间一致,16/20例患者差异<1%。
  • 4DREAL显示最高靶区覆盖(99.8±0.6%,p<0.001),3DREM与4DREM间无差异(分别为99.3±1.3%和99.4±1.1%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite the anticipated clinical benefits of intensity-modulated proton therapy (IMPT), plan robustness may be compromised due to its sensitivity to patient treatment uncertainties, especially for tumours with large motion. In this study, we investigated treatment course-wise plan robustness for intra-thoracic tumours with large motion comparing a 4D pre-clinical evaluation method (4DREM) to our clinical 3D/4D dose reconstruction and accumulation methods. MATERIALS AND METHODS: Twenty patients with large target motion (>10 mm) were treated with five times layered rescanned IMPT. The 3D-robust optimised plans were generated on the averaged planning 4DCT. Using multiple 4DCTs, treatment plan robustness was assessed on a weekly and treatment course-wise basis through the 3D robustness evaluation method (3DREM, based on averaged 4DCTs), the 4D robustness evaluation method (4DREM, including the time structure of treatment delivery and 4DCT phases) and 4D dose reconstruction and accumulation (4DREAL, based on fraction-wise information). RESULTS: Baseline target motion for all patients ranged from 11-17 mm. For the offline adapted course-wise dose assessment, adequate target dose coverage was found for all patients. The target volume receiving 95% of the prescription dose was consistent between methods with 16/20 patients showing differences < 1%. 4DREAL showed the highest target coverage (99.8 ± 0.6%, p < 0.001), while no differences were observed between 3DREM and 4DREM (99.3 ± 1.3% and 99.4 ± 1.1%, respectively). CONCLUSION: Our results show that intra-thoracic tumours can be adequately treated with IMPT in free breathing for target motion amplitudes up to 17 mm employing any of the accumulation methods. Anatomical changes, setup and range errors demonstrated a more severe impact on target coverage than motion in these patients treated with fractionated proton radiotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Visser S, Korevaar EW, Muijs CT, et al. Clinical 3D/4D cumulative proton dose assessment methods for thoracic tumours with large motion. Radiother Oncol. 2023. PMID: 36822356. doi:10.1016/j.radonc.2023.109575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。